Sign In
Buy FTRE
Fortrea Holdings Earnings Calls
| Release date | May 05, 2026 |
| EPS estimate | $0.0300 |
| EPS actual | $0.160 |
| EPS Surprise | 433.33% |
| Revenue estimate | 628.505M |
| Revenue actual | 636.5M |
| Revenue Surprise | 1.27% |
| Release date | Feb 26, 2026 |
| EPS estimate | $0.160 |
| EPS actual | $0.0900 |
| EPS Surprise | -43.75% |
| Revenue estimate | 665.22M |
| Revenue actual | 660.5M |
| Revenue Surprise | -0.710% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.120 |
| EPS Surprise | -25.00% |
| Revenue estimate | 665.222M |
| Revenue actual | 701.3M |
| Revenue Surprise | 5.42% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.0600 |
| EPS actual | $0.190 |
| EPS Surprise | 216.67% |
| Revenue estimate | 623.371M |
| Revenue actual | 710.3M |
| Revenue Surprise | 13.94% |
Last 4 Quarters for Fortrea Holdings
Below you can see how FTRE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $6.58 |
| EPS estimate | $0.0600 |
| EPS actual | $0.190 |
| EPS surprise | 216.67% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $5.74 |
| Aug 01, 2025 | $5.46 |
| Aug 04, 2025 | $6.42 |
| Aug 05, 2025 | $6.56 |
| Aug 06, 2025 | $6.58 |
| Aug 07, 2025 | $7.24 |
| Aug 08, 2025 | $6.58 |
| Aug 11, 2025 | $6.39 |
| Aug 12, 2025 | $7.31 |
| 4 days before | 14.63% |
| 4 days after | 11.09% |
| On release day | 10.03% |
| Change in period | 27.35% |
| Release date | Nov 05, 2025 |
| Price on release | $11.95 |
| EPS estimate | $0.160 |
| EPS actual | $0.120 |
| EPS surprise | -25.00% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $10.03 |
| Oct 31, 2025 | $10.46 |
| Nov 03, 2025 | $10.12 |
| Nov 04, 2025 | $9.70 |
| Nov 05, 2025 | $11.95 |
| Nov 06, 2025 | $11.02 |
| Nov 07, 2025 | $11.25 |
| Nov 10, 2025 | $11.18 |
| Nov 11, 2025 | $11.79 |
| 4 days before | 19.14% |
| 4 days after | -1.34% |
| On release day | -7.78% |
| Change in period | 17.55% |
| Release date | Feb 26, 2026 |
| Price on release | $10.80 |
| EPS estimate | $0.160 |
| EPS actual | $0.0900 |
| EPS surprise | -43.75% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $11.00 |
| Feb 23, 2026 | $10.84 |
| Feb 24, 2026 | $10.32 |
| Feb 25, 2026 | $10.34 |
| Feb 26, 2026 | $10.80 |
| Feb 27, 2026 | $10.72 |
| Mar 02, 2026 | $10.56 |
| Mar 03, 2026 | $10.48 |
| Mar 04, 2026 | $10.38 |
| 4 days before | -1.82% |
| 4 days after | -3.89% |
| On release day | -0.741% |
| Change in period | -5.64% |
| Release date | May 05, 2026 |
| Price on release | $14.53 |
| EPS estimate | $0.0300 |
| EPS actual | $0.160 |
| EPS surprise | 433.33% |
| Date | Price |
|---|---|
| Apr 29, 2026 | $10.56 |
| Apr 30, 2026 | $11.50 |
| May 01, 2026 | $12.18 |
| May 04, 2026 | $12.25 |
| May 05, 2026 | $14.53 |
| May 06, 2026 | $15.64 |
| May 07, 2026 | $15.57 |
| May 08, 2026 | $15.43 |
| May 11, 2026 | $14.99 |
| 4 days before | 37.59% |
| 4 days after | 3.17% |
| On release day | 7.64% |
| Change in period | 41.95% |
Fortrea Holdings Earnings Call Transcript Summary of Q1 2026
Fortrea reported a solid start to 2026 with Q1 revenue of $636.5M and adjusted EBITDA of $47M, reflecting improving commercial traction, operational discipline and cost savings. Book-to-bill was 1.15x in Q1 (1.05x trailing 12 months), driven by stronger biotech engagements, growth in China opportunities, and a favorable mix toward full-service (FSO) work. The company launched Fortrea Intelligent Technology (FIT), an AI-enabled platform integrated with its Xcellerate capabilities intended to improve trial predictability, speed and quality while keeping humans in the decision loop. Operational improvements included revamped site activation, expanded site navigator programs, leadership hires and progress in clinical pharmacology (notably first-in-human patient dosing at Leeds). Financially, Fortrea achieved nearly $16M gross ($9M net) in quarterly cost savings and reiterated full-year 2026 guidance: revenue $2.55B–$2.65B and adjusted EBITDA $190M–$220M. First-quarter cash flow was negative but substantially improved versus prior year (operating cash flow -$17M vs -$124.2M), available liquidity >$0.5B, and a stated path toward mid-teens adjusted EBITDA margins over 3–5 years through revenue diversification, efficiency and continued rightsizing. Management emphasized disciplined execution, focus on customer delivery and cautious, measured reinvestment of savings to support growth and retain talent.
